Vivus Inc News

Vivus Inc News From AOL News

FDA Panel Rejects Experimental Weight Loss Pill

GAITHERSBURG, MD. (July 15) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight. The Food and Drug Administration panel voted 10-6 against Vivus's Qnexa, citing...

Positive Qnexa Review Follows 5 Notable Diet Pill Disasters

(July 13) -- Qnexa, one of three anti-obesity drugs being reviewed by the Food and Drug Administration, effectively reduces body weight among obese patients. That's the bottom line from the FDA today, ahead of a final decision in October. But the agency remains wary of Qnexa's potential side effects: The drug has been...

Vivus Inc News From AOL

THE HUFFINGTON POST

Lorcaserin: FDA Advisers Recommend Approving Weight Loss Drug

Advisers to government health regulators late Thursday recommended that they approve sales of what would be the first new prescription weight-loss drug in the U.S. in more than a decade, despite concerns over cardiac risks.

AOL HEALTHY LIVING

FDA Approves Vivus's Fast-Acting Viagra Rival

Men with erectile dysfunction may not have to plan for sex as far in advance anymore after Vivus Inc won U.S. approval for avanafil, its faster acting rival to Viagra.

Vivus Inc News From the Web

05/30/12 Vivus July volatility elevated into Qnexa PDUFA date Source: Theflyonthewall.com
05/29/12 FDA Obesity Drug Decisions On June 17 And July 27 Will... Source: Seeking Alpha The FDA has two multi-billion dollar decisions to make this summer regarding obesity and weight loss treatments.
05/28/12 These Biotechs May Break Out While Vivus And Arena... Source: Seeking Alpha For a variety of reasons the following biotech stocks may break-out if general Market conditions do not impede that possibility.
05/21/12 Outlooks for Pfizer, Arena and Onyx Following Busy May Source: TheStreet.com My review of the major events in healthcare during the first half of May continues below.
05/16/12 VIVUS option implied volatility low Source: Theflyonthewall.com